|
1
|
Hao J, Zhao P and Chen WQ: Chines cancer
registry annual report. 2012.
|
|
2
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gormally E, Caboux E, Vineis P and Hainaut
P: Circulating free DNA in plasma or serum as biomarker of
carcinogenesis: Practical aspects and biological significance.
Mutat Res. 635:105–117. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Whiteside TL: The potential of
tumor-derived exosomes for noninvasive cancer monitoring. Expert
Rev Mol Diagn. 15:1293–1310. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nakamura T, Sueoka-Aragane N, Iwanaga K,
Sato A, Komiya K, Abe T, Ureshino N, Hayashi S, Hosomi T, Hirai M,
et al: A noninvasive system for monitoring resistance to epidermal
growth factor receptor tyrosine kinase inhibitors with plasma DNA.
J Thorac Oncol. 6:1639–1648. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dawson SJ, Tsui DW, Murtaza M, Biggs H,
Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B,
et al: Analysis of circulating tumor DNA to monitor metastatic
breast cancer. N Engl J Med. 368:1199–1209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Murtaza M, Dawson SJ, Tsui DW, Gale D,
Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS,
et al: Non-invasive analysis of acquired resistance to cancer
therapy by sequencing of plasma DNA. Nature. 497:108–112. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Beaver JA, Jelovac D, Balukrishna S,
Cochran R, Croessmann S, Zabransky DJ, Wong HY, Toro PV, Cidado J,
Blair BG, et al: Detection of cancer DNA in plasma of patients with
early-stage breast cancer. Clin Cancer Res. 20:2643–2650. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Perrone F, Lampis A, Bertan C, Verderio P,
Ciniselli CM, Pizzamiglio S, Frattini M, Nucifora M, Molinari F,
Gallino G, et al: Circulating free DNA in a screening program for
early colorectal cancer detection. Tumori. 100:115–121. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
NCCN Clinical Practice Guidelines in
Oncology. Breast Cancer. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
|
|
11
|
Rakha EA, Reis-Filho JS and Ellis IO:
Impact of basal-like breast carcinoma determination for a more
specific therapy. Pathobiology. 75:95–103. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Diehl F, Schmidt K, Choti MA, Romans K,
Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al:
Circulating mutant DNA to assess tumor dynamics. Nat Med.
14:985–990. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Forshew T, Murtaza M, Parkinson C, Gale D,
Tsui DW, Kaper F, Dawson SJ, Piskorz AM, Jimenez-Linan M, Bentley
D, et al: Noninvasive identification and monitoring of cancer
mutations by targeted deep sequencing of plasma DNA. Sci Transl
Med. 4:136ra682012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Newman AM, Bratman SV, To J, Wynne JF,
Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, et
al: An ultrasensitive method for quantitating circulating tumor DNA
with broad patient coverage. Nat Med. 20:548–554. 2014. View Article : Google Scholar : PubMed/NCBI
|
